- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03176888
Health Benefits of HIT for Breast Cancer Patients
The Efficacy of Reduced-exertion High-intensity Interval Training for Improving Health and Well-being in Newly Diagnosed Female Breast Cancer Patients
Study Overview
Status
Conditions
Detailed Description
This study involves a randomised controlled trial: study participants will be randomly allocated to either a group who will receive the care that they would normally have received if they would not have been in the study (control group), and a group who will receive the same standard care but will also be asked to follow a novel supervised exercise routine three times per week before their surgery and for up to 6 weeks after surgery, as well as some psychological support.
Up to 30 newly-diagnosed female breast cancer patients will be recruited. Following written informed consent, participants will be invited for a baseline testing session. This will involve a fasting blood sample (ideally at a time when the patient's medical team would take a blood sample anyway). The investigators will analyse this sample for a number of markers of health, such as blood sugar and fat levels, and markers of inflammation. The investigators will measure the patients' height with a stadiometer, and weight and body fat percentage using a special set of scales. The investigators will ask patients to complete several questionnaires that ask questions about their current well-being. Finally the investigators will measure the patients' handgrip strength as well as their fitness levels. The grip strength test involves squeezing a handheld device as hard as possible for a few seconds. The fitness test involves cycling on a stationary bike with a gradually increasing resistance until the patient cannot continue any longer because of fatigue. In this test the investigators will ask patients to breathe through a tube to determine the maximal amount of oxygen they can take up during exercise. This measure (termed VO2max) is one of the best health markers that can be measured: it is the best predictor of future risk of chronic disease or premature death. All testing sessions will be performed at the Manor Hospital in Oxford (unless the equipment required for the analysis of VO2max is not available for a period of time, in which case patients will be invited to attend Oxford Brookes campus for the fitness test; this is a 4-minute drive from the Manor Hospital).
Ideally, the blood samples will be taken in a fasted state (i.e. in the morning without having had breakfast), whereas the fitness test will be done after the patient has last had some food. The investigators will therefore provide the participants with a light snack after the blood sample has been taken. In case a patient cannot attend the hospital in the morning in a fasted state then they will arrange the session at a later time of day and the patient will not be required to be fasted (leading to loss of some of the secondary outcome measures which require a fasted state).
After the baseline testing has been completed the investigators will tell patients whether they will be in the control group or in the exercise group. Patients in the control group will receive their standard care as if they would not have participated in the study. The research team will not interact with these patients until the second testing session. Patients in the exercise group will be invited to perform 3 fully supervised exercise sessions per week at the Manor Hospital. These exercise sessions will involve 10 minutes of cycling at a low intensity, but with 2 brief cycle sprints after 2 and 6 minutes. The sprints will last 10 seconds in the first week of training, 15 seconds in the second week, and 20 seconds from week 3 onward. Training sessions will be stopped at least 2 days prior to the scheduled surgery date.
Surgery will interrupt the exercise programme. Between 7 and 10 days post-surgery, or when the consultant breast surgeon deems appropriate, all patients will undergo post-surgery testing. Testing procedures will be identical as those for baseline testing.
Following post-surgery testing, patients in the exercise group will resume the exercise programme. The duration of the sprints will restart at 10 seconds in the first week, 15 seconds in the second week, and 20 seconds in the remaining weeks. The exercise routine will be continued until follow-up treatment or for a period of up to 6 weeks. Before or after one of the 3 weekly exercise sessions, patients will receive a 30/40-minute face-to-face session with a psychologist. The aim of these sessions will be to reduce emotional distress, improve mental adjustment, promote a sense of personal control over current experience, develop effective coping strategies for dealing with cancer-related difficulties, and open expression of emotion. If patients cannot attend psychological support sessions then they will be offered the opportunity to catch up through a session over the phone.
Approximately 3 days following the final training session patients will undergo end-of-trial testing, identical to the previous two testing sessions. Patients in the control group will undergo this testing session at a time-point equivalent to that of patients in the exercise group.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7RP
- Manor Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recent diagnosis of biopsy-proven primary invasive breast cancer
- Pre- or post-menopausal women
- World Health Organisation Performance status 0-2
- No distant metastasis
On a treatment plan of:
- surgery (breast conservation surgery or mastectomy with or without reconstruction, including axillary surgery)
- Adjuvant treatment with hormonal therapy and/or radiotherapy
- Adjuvant chemotherapy with or without anti-Her-2 therapy
- Can start the study within 1 week of diagnosis and prior to surgery
- Have surgery arranged within 1-4 weeks of diagnosis
- All receptor statuses are eligible
Exclusion Criteria:
- BMI > 35 kg·m-2
- Age < 35 y or > 60 y
- Men
- Verbal self-report of undertaking five or more structured exercise sessions per week, perceived as being moderate-to-vigorous intensity, and each session being ≥ 30 minutes in duration
- Contraindications to exercise as determined using the Physical Activity Readiness Questionnaire (PAR-Q)
- Any known significant cardiovascular (except controlled hypertension), pulmonary (except treated/controlled asthma) or metabolic disease (except hypercholesterolemia or type II diabetes)
- Auto-immune disease or exercise-limiting inflammatory arthritis
- Distant metastasis
Secondary breast cancer or previous diagnosis of invasive cancer and treatment within last 5 years except
- Localised basal cell carcinoma or squamous cell carcinoma of skin
- In situ melanoma
- Cervical intraepithelial neoplasia (CIN)
- Neoadjuvant chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exercise
Patients in the Exercise group will follow a fully-supervised exercise routine (Reduced-exertion, high-intensity interval training (REHIT)) with 3 weekly 10-minute training sessions consisting of easy cycling interspersed with 2 brief 'all-out' cycle sprints.
Patients in this group will also be offered up to 6 sessions of cognitive behavioral therapy.
The duration of the intervention will be the weeks between enrolling in the study and surgery (~1-4 weeks), as well as an additional period of up to 6 weeks following surgery.
|
As in arm/group description
Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey & Greer (2012)
|
No Intervention: Standard care
Patients allocated to the Standard Care group will receive the care they would have also received if they would not have participated in the study.
They will however undergo the same testing sessions as patients in the Exercise group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in maximal aerobic capacity (VO2max)
Time Frame: From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
VO2max is a measure of the maximal amount of exercise that can be consumed and used during exercise.
It is one of the best predictors of future risk of morbidity and mortality.
An increase in VO2max represents a positive change in health.
The primary outcome measure is change in VO2max from baseline to 1 week post-surgery and 7 weeks post-surgery.
|
From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in homeostatic model assessment of insulin resistance (HOMA-IR)
Time Frame: From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
HOMA-IR is a measure of risk of type 2 diabetes and metabolic disease.
|
From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Change in blood lipid profile
Time Frame: From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
This includes circulating levels of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides.
These are common health markers.
|
From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Change in blood pressure
Time Frame: From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Blood pressure is a common health marker.
|
From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Change in body mass index (BMI)
Time Frame: From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Height and weight will be measured to calculate BMI (in kg/m^2).
BMI is a common health marker.
|
From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Change in grip strength
Time Frame: From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Maximal isometric grip strength assesses how hard a person can squeeze their fist.
This is a good marker of risk of future morbidity.
|
From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Change in mental well-being
Time Frame: From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Questionnaires will be used to determine changes in mental well-being.
|
From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Change in body fat percentage
Time Frame: From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Body fat percentage (as determined using bioimpedance scales) is a common health measure.
|
From baseline, to 1 week post-surgery and 7 weeks post-surgery.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Niels BJ Vollaard, PhD, University of Stirling
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017 0105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on Reduced-exertion, high-intensity interval training (REHIT)
-
University of StirlingUniversity of Edinburgh; Swansea University; University of Worcester; California...Recruiting
-
University of BathWithdrawnProstate CancerUnited Kingdom
-
University of StirlingSwansea UniversityCompletedHealth BehaviorUnited Kingdom
-
University of StirlingRecruitingGeneral HealthUnited Kingdom
-
University of StirlingNot yet recruitingMental Health Wellness 1United Kingdom
-
University of StirlingSwansea University; University of WorcesterRecruiting
-
University of ValenciaCompleted
-
University of StirlingRecruitingHealth BehaviorUnited Kingdom
-
University of MichiganCompletedGlucose IntoleranceUnited States
-
Universidad SurcolombianaMaciste Macias; Gilberto AstaizaRecruiting